Hybrid coronary revascularization: Time for a new comparator?

Area of Science:

• Cardiovascular Surgery
• Interventional Cardiology

Background:

• This meta-analysis compares hybrid coronary revascularization (HCR) with coronary artery bypass grafting (CABG) for intermediate-term outcomes.
• Investigates major adverse cardiac and cerebrovascular events (MACCE) as a primary endpoint.

Discussion:

• HCR demonstrates feasibility with potentially lower perioperative morbidity compared to CABG.
• No significant difference in MACCE was observed between HCR and CABG in the intermediate term.
• Repeat revascularization rates are comparable between current drug-eluting stents and CABG.

Key Insights:

• Hybrid coronary revascularization (HCR) presents a comparable safety and efficacy profile to traditional bypass surgery (CABG) for intermediate-term MACCE.
• HCR offers advantages in terms of feasibility and reduced perioperative complications.
• The advent of advanced drug-eluting stents necessitates a re-evaluation of comparators in future HCR trials.

Outlook:

• Future clinical trials for HCR should consider multi-vessel percutaneous coronary intervention (PCI) as the new benchmark comparator.
• Further research is warranted to fully elucidate the long-term benefits and optimal patient selection for HCR.